iMD Companies, Inc. Acquires Riize, LLC

ModuleMD Acquires Diversified Health Care Management and MedEase Practice Management

September 4, 2023

Healthcare Services

ModuleMD has acquired Diversified Health Care Management, Inc. and MedEase (DBA Professional Management Services, Inc.) to expand its revenue cycle management (RCM) capabilities and client footprint in the northwestern United States. The deal brings the target teams and technology into ModuleMD’s physician‑designed SaaS platform to accelerate automation across claims management using RPA, analytics and AI.

WebMD Health Corp. Acquires Healthwise Operating Assets

March 4, 2024

Healthcare Services

WebMD Health Corp., an Internet Brands company, acquired the operating assets of Healthwise — including content, products, technology, client relationships and certain trademarks — and will fold most of Healthwise's team into WebMD Ignite. The deal expands WebMD Ignite's patient and member engagement capabilities and footprint (now serving more than 650 healthcare organizations); financial terms were not disclosed.

MedImpact Acquires Elixir Solutions From Rite Aid

February 1, 2024

Healthcare Services

MedImpact Healthcare Systems has completed the acquisition of Rite Aid’s Elixir Solutions business for about $576.5 million. The deal expands MedImpact’s clinical, technology, health risk management and consumer empowerment capabilities as part of its reinvestment strategy and strengthens its position as an independent provider of health solutions and PBM services.

OptimizeRx Acquires RMDY Health

September 5, 2019

Cloud & SaaS

OptimizeRx Corporation (NASDAQ: OPRX) agreed to acquire RMDY Health, a digital therapeutics SaaS platform, for $16 million in cash and equity ($8M cash, $8M equity). The deal expands OptimizeRx's patient engagement capabilities into digital therapeutics and adds new client segments including payers, MedTech and medical associations; RMDY will retain its technology team in Tel Aviv while U.S. personnel will operate from OptimizeRx's U.S. offices.

Bristol Myers Squibb Acquires RayzeBio for Approximately $4.1 Billion

December 26, 2023

Biotechnology

Bristol Myers Squibb will acquire radiopharmaceutical developer RayzeBio in an all-cash tender offer of $62.50 per share, valuing RayzeBio at approximately $4.1 billion (about $3.6 billion net of cash). The acquisition brings RayzeBio's actinium-based radiopharmaceutical platform, a Phase 3 lead program (RYZ101) and in-house radiopharmaceutical manufacturing capabilities into Bristol Myers Squibb's oncology franchise to accelerate development and commercialization of targeted radiopharmaceutical therapeutics.

Novo Holdings Acquires The Ritedose Corporation

January 4, 2022

Pharmaceuticals

Novo Holdings A/S has agreed to acquire The Ritedose Corporation from AGIC Capital and Humanwell. Ritedose, a Columbia, South Carolina-based sterile pharmaceutical manufacturer specializing in blow-fill-seal (BFS) technology for ophthalmic, respiratory and vaccine products, employs more than 400 people and will remain led by CEO Jody Chastain; the transaction is expected to close in Q1 2022.